title: High-dose, short-duration ribavirin aerosol therapy compared with standard ribavirin therapy in children with suspected respiratory syncytial virus infection.
abstract: Children with suspected respiratory syncytial virus infection were examined prospectively in a randomized evaluation of standard ribavirin aerosol therapy (6 gm/300 ml water for 18 hours daily) compared with high-dose, short-duration ribavirin aerosol therapy (6 gm/100 ml water given for a period of 2 hours three times a day) by means of an oxygen hood (n = 20) or a ventilator (n = 12). Viral shedding was quantitated daily; clinical observations were recorded daily by 2 physicians aware and one unaware of treatment assignments. Study characteristics evaluated at entry were not significantly different in the high-dose and the standard-dose groups. Viral titers and clinical scores decreased similarly in both groups during the study; pulmonary function test results were also similar at discharge in children not receiving mechanical ventilation. Potential complications related to aerosol therapy were noted in three patients (one hood patient who was receiving standard therapy; two patients with an endotracheal tube in place who were receiving high-dose therapy); substantial crystallization was noted in the tubing of the patients undergoing intubation and receiving high-dose therapy. Environmental sampling revealed that ribavirin was nearly undetectable near patients supported by mechanical ventilation who were receiving either form of therapy, and was significantly decreased on a daily basis in patients without an endotracheal tube who were receiving high-dose therapy compared with those receiving standard therapy. The effects of high-dose, short-duration aerosol ribavirin therapy were similar to those of standard-dose therapy in our study patients and resulted in a decreased release of ribavirin into the room of patients receiving therapy by means of an oxygen hood.
authors.affiliation: Department of Microbiology and Immunology, Baylor College of Medicine, Houston, Texas 77030.
authors.forename: J A
authors.initials: JA
authors.lastname: Englund
authors.forename: P A
authors.initials: PA
authors.lastname: Piedra
authors.forename: Y M
authors.initials: YM
authors.lastname: Ahn
authors.forename: B E
authors.initials: BE
authors.lastname: Gilbert
authors.forename: P
authors.initials: P
authors.lastname: Hiatt
mesh_terms: D000336:Aerosols; D000391:Air Microbiology; D002648:Child; D002675:Child, Preschool; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D010102:Oxygen Inhalation Therapy / Q000295:instrumentation; D018357:Respiratory Syncytial Virus Infections / Q000188:drug therapy* / Q000628:therapy; D012136:Respiratory Syncytial Viruses / Q000302:isolation & purification; D012254:Ribavirin / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D000336:Aerosols; D012254:Ribavirin